Testimonials







"Thank you for putting on your therapeutic area webinars. They’re great! What I like most about them is that I can catch up on the state-of-the-art commercial thinking and apply it to early development efforts."

Thomas A. Collet, PhD
President, CEO, and Co-founder
Phrixus Pharmaceuticals


"We are extremely pleased with the exceptional quality of the product develoment and commercialization strategy work that Defined Health conducted for Lineagen. Defined Health’s research was rigorous, credible and relevant, and was vital in helping Lineagen develop a clear path and forward-looking strategy.  In fact, Defined Health's research directly led to Lineagen's first commercialized service, which is now a revenue-generating business for Lineagen."

Michael S. Paul, PhD
President and CEO
Lineagen, Inc


"Topotarget recently engaged Defined Health to design and implement an evaluation of a major oncology drug asset. The project was completed on schedule; the deliverables were as promised and the participation by the DH Team was professional and extremely responsive. Topotarget was completely satisfied with the value delivered and intends to engage this expert team as required in the future. The DH extensive oncology experience was a major factor in their selection and the Topotarget expectations were met."

John L. Parsons Jr.
Chief Commercial Officer TopoTarget A/Sr
President TopoTarget USA, Inc.


"We approached Defined Health with a unique challenge: Help a charity, The Leukemia & Lymphoma Society (LLS), understand in great detail the treatment and research landscape of the hematological malignancies and use this information to define unmet needs against which LLS could deploy resources (its $100 MM annual mission budget) to accelerate the development of new therapies.  The work product created by the professional staff at DH greatly exceeded our expectations.  The implementation of DH recommendations has resulted in an exciting new research funding philosophy and strategic research direction for LLS."

Louis J. DeGennaro, PhD
Executive Vice President, Chief Mission Officer
The Leukemia & Lymphoma Society


"I have used Defined Health on many occasions over the past 10+ years on projects that required significant strategic as well as market assessment decision making skills. They have delivered on every project and have met deadlines which were very tight. What I appreciate most about the DH team is the sense of 'getting it done right'. They will not consider a job done unless it is done to the satisfaction of the client. Another key attribute I have come to rely on is DH's 'bench depth' and the fact that Ed has a group of extremely bright individuals to pull from to solve problems. I am very happy to recommend Defined Health."

Terry J. Conrad
President
Photocure, Inc.


"I have engaged Defined Health on multiple projects and always found their insights into oncology, the marketplace, emerging trends and technologies to be extremely valuable.  Defined Health has a deep understanding of the science and evolving marketplace in oncology and their work has played an integral role in shaping various therapeutic and molecule strategies at Lilly."

Rod J. Taylor
Marketing Director, Oncology New Product Planning
Eli Lilly and Company


"When combining complex scientific analyses with strategic considerations, Defined Health is the definitive source of the best advice. We have worked together on a broad range of projects and always encountered the same professionalism and critical insight."

Claudia Hirawat
Senior Vice President, Corporate Development
PTC Therapeutics, Inc.


“We've worked with Defined Health since our start-up. They are the poster child for value-added product strategy and market analysis. They don't just tell you what you want to know, they tell you what you don't know but should.”

Clive A. Meanwell, MD, PhD
Chairman & CEO
The Medicines Company


"I have been a client of Defined Health for over 6 years, both at my present company and my previous one. I have utilized DH whenever I have projects involving complex commercialization issues, including cutting edge clinical approaches requiring keen scientific understanding. They have provided me with critical insights, in a timely fashion, that have helped our decision-making process and that have ultimately helped shape the course of some of our key development programs."

Jean-Sylvain Demelier
Vice President, Global Oncology Marketing
Bayer HealthCare Pharmaceuticals